Inhibikase Therapeutics Q3 EPS $(0.86) Beats $(1.19) Estimate, Sales $79.57K Up From $7.29K YoY
Portfolio Pulse from totan@benzinga.com
Inhibikase Therapeutics (NASDAQ:IKT) reported Q3 earnings with a loss of $(0.86) per share, surpassing the $(1.19) estimate, marking a 27.73% beat and a 20.37% improvement from last year's $(1.08) loss per share. Sales soared to $79.57K, a 991.33% increase from $7.29K in the same quarter of the previous year.
November 14, 2023 | 9:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Inhibikase Therapeutics reported a smaller-than-expected Q3 loss and a significant increase in sales compared to the same period last year.
The positive earnings report, with a loss per share that was significantly better than analyst expectations and a substantial year-over-year increase in sales, is likely to be viewed positively by investors. This could lead to a short-term increase in the stock price as the market reacts to the company's improved financial performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100